Rhythm Pharmaceuticals has granted RareStone exclusive rights to develop and commercialize setmelanotide in China. The drug is used to treat severe obesity and hyperphagia. Rhythm will receive $12 million in cash and stock in RareStone, and will be entitled to receive up to $63.5 million, if certain development milestones are reached, and royalties on sales.